What are the recommended calcium, vitamin D, lifestyle, and pharmacologic therapies for osteoporosis in a postmenopausal woman or a man aged ≥ 50 with a T‑score ≤ ‑2.5 or a prior fragility fracture?

Osteoporosis Management Recommendations

For postmenopausal women or men ≥50 years with osteoporosis (T-score ≤-2.5 or prior fragility fracture), initiate bisphosphonates as first-line pharmacologic therapy alongside calcium and vitamin D supplementation, exercise, and fall prevention strategies 1.

Pharmacologic Treatment Algorithm

First-Line Therapy

• Start with oral bisphosphonates (alendronate or risedronate) as generic formulations for both postmenopausal women and men with primary osteoporosis 1
• Bisphosphonates demonstrate the most favorable balance of benefits, harms, cost, and patient preferences among all osteoporosis medications 1
• High to moderate certainty evidence shows bisphosphonates reduce fracture risk without increasing serious adverse events compared to placebo 1

Treatment Duration and Drug Holidays

• Treat with bisphosphonates for 5 years, then reassess 1
• After 5 years, consider stopping unless the patient has strong indications for continuation (very high fracture risk, new fractures during treatment) 1
• Evidence shows extending beyond 5 years probably reduces vertebral fractures but not other fractures, while increasing long-term harms like osteonecrosis of the jaw and atypical femoral fractures 1

Second-Line Options

• Use denosumab (RANK ligand inhibitor) only if bisphosphonates are contraindicated or cause adverse effects 1
• This applies to both women and men, as treatment benefits and harms do not differ by sex 1
• Critical caveat: Denosumab has rapid offset after discontinuation with serious rebound fracture risk—must transition to bisphosphonates if stopping 1

Anabolic Agents (High-Risk Patients)

• Reserve teriparatide or romosozumab for patients at very high fracture risk 1
• Use for 1-2 years maximum, then mandatory transition to antiresorptive therapy to preserve gains and prevent rebound vertebral fractures 1, 2
• Teriparatide may increase serious adverse events and withdrawal rates 1

Non-Pharmacologic Essentials

Calcium and Vitamin D

• Ensure adequate calcium intake: 1,000 mg daily 3
• Vitamin D supplementation: minimum 800 IU (20 mcg) daily to achieve serum 25(OH)D levels ≥50 nmol/L (20 ng/mL) 4
• These are foundational requirements for all patients with osteoporosis, regardless of pharmacologic therapy 1, 5
• Calcium and vitamin D alone are insufficient for fracture prevention in established osteoporosis but are necessary adjuncts to pharmacotherapy 6, 7

Lifestyle Modifications

• Exercise prescription: balance, functional, and resistance training twice weekly 8
• Smoking cessation and moderate alcohol intake 6
• Maintain healthy body weight through balanced diet 2

Fall Prevention

• Systematically assess and address fall risk, as falls cause most fractures in older adults 1, 8
• Review medications that increase fall risk (sedatives, antihypertensives, polypharmacy) 1, 9
• Implement home safety modifications and balance training 8

Key Clinical Considerations

Monitoring and Adherence

• Encourage adherence to prescribed therapy—most patients discontinue within 1 year despite proven efficacy 6
• Prescribe generic bisphosphonates when possible to reduce cost barriers 1
• Individualize discontinuation decisions based on baseline fracture risk, medication type, treatment duration, and half-life in bone 1

Common Pitfalls to Avoid

• Do not use vitamin D and calcium alone in patients meeting pharmacologic treatment criteria—they require bisphosphonates 1, 7
• Never stop denosumab without transitioning to bisphosphonates—rebound fracture risk is severe 1
• Do not continue anabolic agents beyond 1-2 years without switching to antiresorptives 1, 2
• Do not routinely extend bisphosphonates beyond 5 years without reassessing fracture risk versus harm 1

Special Populations

• Older patients with polypharmacy or high fall risk need individualized treatment selection considering drug interactions and comorbidities 1
• Men with primary osteoporosis follow the same treatment algorithm as postmenopausal women 1

The 2023 American College of Physicians guideline 1 provides the strongest and most recent evidence base for this algorithmic approach, emphasizing bisphosphonates as first-line therapy with clear guidance on treatment duration and sequencing.